Kolding L, Ehrenstein V, Pedersen L, et al. - Given the increased use of attention-deficit/hyperactivity disorder (ADHD) medications in pregnancy and the possible underestimation of their severe teratogenic effects that may cause fetal death or termination of pregnancy in studies on how safe these medications are during pregnancy that are restricted to live births, researchers here assessed data from both prenatal and postnatal diagnoses of major malformations to address this limitation. In this nationwide registry-based study, 364,012 singleton pregnancies in Denmark were assessed. During the study period, an increase in the prevalence of first-trimester exposure to ADHD medication was observed from 0.05% in 2008 to 0.27% in 2013, with most (473/569) of the exposures being to methylphenidate. Data overall indicated no correlation of exposure to methylphenidate with an increased risk of malformations, though an increased risk of cardiac malformations was observed with a number needed to harm of 92 based on 12 cases among the exposed.